AcuityMD, a leading technology provider to the MedTech industry, has announced the launch of AcuityMD Care Journeys to help MedTech companies efficiently bring their innovations to the right patients by harnessing longitudinal, patient-level data for more precise targeting.
The company says that Care Journeys empowers commercial teams to demonstrate the value of their products to physicians, hospitals, and independent delivery networks (IDNs), driving revenue and improving patient care.
If a MedTech company is launching a new device or running a clinical trial, Care Journeys uncovers and prioritises opportunities to treat patients with complex clinical histories. AcuityMD says that Care Journeys affords MedTech teams accuracy and precision when identifying patient populations that can benefit the most from their innovation, especially groups with comorbidities, dual diagnoses, or at the intersection of multiple conditions and procedures.
Early adopter icotec Medical is using Care Journeys to uncover sites-of-care that treat patients with spinal tumours as well as the spine surgeons and radiation oncologists that treat them. icotec makes a unique carbon composite surgical screw for patients suffering from metastatic spine disease.
These radiolucent, non-metallic screws produce little-to-no artifact in diagnostic imaging such as computer tomography (CT) scans and magnetic resonance imaging (MRI), which leads to safer delivery of adjuvant radiation therapy and improved monitoring and follow-up care. icotec has also been approved for a new indication for spinal infections and has leveraged Care Journeys to create its commercialisation strategy, inform decisions on head count and manufacturing, identify partner sites of care, and more as it prepares for launch.
“Finding the right targets with Care Journeys has been like going from holding a candle in a dark room to shining an industrial flashlight,” explained Scott McKay, product manager at icotec Medical. “Care Journeys enables our organisation to quickly identify the appropriate patient population in target accounts and the key stakeholders in each of those sites of care that we have been struggling to find for years. Care Journeys’ insights also enrich our partnership with surgeons and healthcare systems, empowering us to bring more value to our partners and help them identify and treat more patients with our unique technology.”
Synchron Inc. is leveraging Care Journeys to identify and enrol patients in a pre-clinical trial for its brain-computer interface (BCI) that allows paralysed patients to control digital outputs, providing a breakthrough treatment for Amyotrophic Lateral Sclerosis (ALS) patients. With the next trial starting in 2025, Synchron faced challenges efficiently identifying the right ALS patients for trial participation.
“As we gear up for the BCI trial, AcuityMD Care Journeys’ insights into this specific ALS patient population, treatment centers, key stakeholders, and potential referrals has been invaluable,” said John McKinley, senior director of medical education and training at Synchron. “Care Journeys’ multidimensional data is expanding our search beyond existing connections to new geographies and has helped us quickly hone in on viable clinical trial sites. This intelligence will also be critical to our post-approval commercialisation strategy.”
“More precision in targeting ultimately results in a higher-quality sales pipeline, which supports the entire MedTech commercialisation process,” said Ross Feinstein, vice president of product at AcuityMD. “Care Journeys makes it fast and easy to not only pinpoint complex patient populations, but also harness clinical market share, patient data, and quality of care insights to become trusted advisors to providers, ultimately improving patient care.”
